Q-omics provides the consensus-scored SFTPA1 profile across patient tissues and cancer cell-line models. SFTPA1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SFTPA1 is differentially expressed in 4, with the highest sampling consensus in LUAD. Additionally, SFTPA1 RNA expression shows 12,299 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, LUAD, and LSCC as cancer lineages where SFTPA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SFTPA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SFTPA1 survival associations across molecular data types. SFTPA1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SFTPA1 RNA expression–survival associations across cancer types. High SFTPA1 expression shows unfavorable associations in LUSC and KIRC, but favorable associations in HNSC, ESCA, LGG and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SFTPA1 RNA expression.
This table summarizes SFTPA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SFTPA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SFTPA1 shows lower tumor expression in LUAD, LUSC and COAD and higher tumor expression in THCA. The LUAD box plot shows higher SFTPA1 RNA expression in normal versus tumor tissue (log2 FC = −6.021, t-test p < 0.001).
This table shows molecular features associated with SFTPA1 in patient tissues and cancer cell lines. In patient samples, SFTPA1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SFTPA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
